Level C· Early human research exploring benefitsRetrospective StudyPubMedOpen access

Association between cellular characteristics and clinical outcomes following autologous micro-fragmented adipose tissue injection for knee osteoarthritis.

Fan C., Zhao Z., Liang B., Xing Y., Li S., Xiao K.

Retrospective Study with a reported sample of 40 on Knee Osteoarthritis, Osteoarthritis, published in Front Bioeng Biotechnol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
Front Bioeng Biotechnol (2026)
Country
Switzerland
Reported sample size
40
Source database
PubMed
PMID
42305813
PMCID
PMC13265573
DOI
10.3389/fbioe.2026.1843722

Abstract (original English)

Autologous micro-fragmented adipose tissue (aMFAT) has emerged as a promising orthobiologic therapy for knee osteoarthritis (KOA). However, the relationship between the cellular characteristics of aMFAT products and clinical outcomes remains unclear. This retrospective single-center study included 40 patients with symptomatic KOA (Kellgren-Lawrence grade II-III) who received a single intra-articular injection of aMFAT. Clinical outcomes were assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at baseline, 3 months, and 6 months. Cytological analyses were performed in a subgroup of 14 patients, including cell viability, total nucleated cell count, viable nucleated cell load, and cell subpopulation composition. Subgroup and correlation analyses were conducted to explore associations between cellular characteristics and clinical outcomes. Significant improvements in WOMAC total and subscale scores were observed at both 3 and 6 months compared with baseline (P < 0.05). At 6 months, 97.5% of patients achieved the minimal clinically important difference. In the cytological subgroup, both cell viability and viable nucleated cell load were positively correlated with clinical improvement, with viable nucleated cell load demonstrating a stronger association (r = 0.93 vs. 0.84). Patients with higher cell load showed significantly greater and more sust

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research